ARVN

Neutral

Arvinas (NASDAQ: ARVN) gains first PROTAC FDA nod as Q1 2026 swings to loss

Arvinas reported a significant milestone with FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC protein degrader, for ESR1-mutated ER+/HE...

Stock Titan 8 hours ago 0

Bearish

Will Arvinas (NASDAQ:ARVN) Spend Its Cash Wisely?

Arvinas (NASDAQ: ARVN), a biotechnology company, has a cash runway of 2.5 years based on its December 2025 cash balance of US$685 million and an annua...

Simply Wall Street 8 hours ago 0